Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-25

Study Completion Date

2013-03-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to evaluate the effects of PLX3397 on male subjects with CRPC.

Secondary objectives include evaluating the safety and tolerability of PLX3397 and the anti-tumor effects that PLX3397 has on the the subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin

NCT00611962

Neoplasms, Germ Cell and Embryonal

COMPLETED PHASE2

Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

NCT00193609

Neoplasms, Unknown Primary

COMPLETED PHASE2

Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

NCT00536809

Neoplasms, Colorectal

COMPLETED PHASE1

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

NCT01525602

Solid Tumors

COMPLETED PHASE1

Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

NCT00186277

Bladder Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PLX3397

Participants will take daily oral dose of PLX3397 for 28 day cycles. Participants will continue to take PLX3397 until disease progression or toxicity.

Group Type EXPERIMENTAL

PLX3397

Intervention Type DRUG

Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PLX3397

Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed prostate cancer, currently with objective progressive disease.
* Castrate level of testosterone (\<50 ng/dL).
* Baseline circulating tumor cell (CTC) count ≥10/7.5 mL blood.
* Archival tumor tissue (unstained sections, paraffin block, or frozen tumor tissue) has been requisitioned for shipment to the central laboratory.
* Karnofsky performance status of 80-100.
* Adequate organ and marrow function.

Exclusion Criteria

* The subject has received:

* Any systemic chemotherapy (including investigational agents) within 4 weeks (with the exception of nitrosoureas/mitomycin C within 6 weeks), of the first dose of study treatment, OR
* Biological agents (antibodies, immune modulators, cytokines, or vaccines) within 6 weeks of the first dose of study treatment, OR
* Hormonal anticancer therapy (not including LHRH agonists or antagonists) within 2 weeks before the first dose of study treatment. Specific restrictions on prior hormonal and other anticancer treatments are detailed in inclusion criterion, OR
* Small-molecular kinase inhibitors or any other type of investigational agent within 4 weeks before the first dose of study treatment or 5 half-lives of the compound or active metabolite, whichever is shorter.
* The subject has received drugs used to control loss of bone mass (e.g., bisphosphonates) within 4 weeks prior to the first dose of study treatment.
* The subject has symptomatic or uncontrolled brain metastasis or epidural disease requiring current treatment including steroids and anti-convulsants.
* The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) \>450 ms at screening.
* The subject has uncontrolled or significant intercurrent illness including, but not limited to, the following conditions:

* Cardiovascular disorders such as symptomatic congestive heart failure (CHF), \*Uncontrolled hypertension
* Unstable angina pectoris, clinically-significant cardiac arrhythmias
* History of stroke (including transient ischemic attack \[TIA\] or other ischemic event) within 6 months of study treatment
* Myocardial infarction within 6 months of study treatment
* History of thromboembolic event requiring therapeutic anticoagulation within 6 months of study treatment or main portal vein or vena cava thrombosis or occlusion.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No